Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E89.40 EPS (ttm)0.47 Insider Own0.20% Shs Outstand2.43B Perf Week1.97%
Market Cap101.20B Forward P/E14.86 EPS next Y2.80 Insider Trans0.00% Shs Float2.43B Perf Month8.59%
Income1.14B PEG6.53 EPS next Q- Inst Own9.00% Short Float0.29% Perf Quarter10.64%
Sales35.01B P/S2.89 EPS this Y-89.20% Inst Trans1.45% Short Ratio1.85 Perf Half Y-2.49%
Book/sh0.58 P/B71.67 EPS next Y0.97% ROA1.60% Target Price47.00 Perf Year11.64%
Cash/sh2.57 P/C16.17 EPS next 5Y13.70% ROE78.60% 52W Range36.69 - 43.93 Perf YTD9.46%
Dividend2.00 P/FCF- EPS past 5Y-28.90% ROI8.60% 52W High-5.37% Beta0.97
Dividend %4.81% Quick Ratio0.60 Sales past 5Y0.40% Gross Margin68.10% 52W Low13.32% ATR0.42
Employees101192 Current Ratio0.90 Sales Q/Q20.70% Oper. Margin9.30% RSI (14)82.76 Volatility0.99% 1.03%
OptionableYes Debt/Eq16.72 EPS Q/Q171.00% Profit Margin3.30% Rel Volume0.73 Prev Close41.56
ShortableYes LT Debt/Eq13.04 EarningsJan 25 Payout426.60% Avg Volume3.79M Price41.57
Recom2.00 SMA204.78% SMA507.18% SMA2003.02% Volume2,760,195 Change0.02%
Oct-20-16Initiated Investec Buy
Sep-23-16Initiated Piper Jaffray Overweight
Jul-14-16Upgrade Jefferies Hold → Buy
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-27-17 11:23AM  Why I'm Optimistic About GlaxoSmithKline
10:36AM  Eli Lilly and Co.s New Products Portfolio
Feb-25-17 09:34AM  Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc at Motley Fool
Feb-24-17 07:27AM  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
Feb-23-17 10:12AM  Top Ranked Growth Stocks to Buy for February 23rd
09:58AM  Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
05:00AM  Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma Business Wire
Feb-22-17 05:08PM  Pfizer's Leukemia Candidate Gets Priority Review in U.S.
04:31PM  Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs
12:42PM  Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments at
Feb-21-17 01:38PM  Korn Ferry Futurestep Partners with GlaxoSmithKline to Support Talent Acquisition Business Wire
Feb-19-17 10:14PM  If You Want Yield, Look to the UK
Feb-18-17 12:09PM  2 High-Yield Dividend Stocks That Are Ridiculously Cheap at Motley Fool
Feb-17-17 04:46PM  Inside Sanofis Revenues in 4Q16
02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
Feb-16-17 04:25PM  Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
04:19PM  Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y
09:05AM  GlaxoSmithKlines Valuation Compared to Its Peers
07:35AM  GlaxoSmithKlines Consumer Healthcare Reports Growth in 4Q16
03:29AM  British Blue Chips Snub Investor Calls to Show CEO Pay Ratio at Bloomberg
Feb-15-17 10:36AM  GlaxoSmithKlines Vaccines Business Reported Growth in 4Q16
10:08AM  AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates
07:37AM  GlaxoSmithKlines HIV Business in 4Q16
Feb-14-17 04:39PM  ETFs with exposure to GlaxoSmithKline Plc : February 14, 2017
04:19PM  Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet
03:19PM  GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming at Motley Fool
03:05PM  Performance of GlaxoSmithKlines Pharmaceuticals Segment in 4Q16
01:35PM  4Q16 Performance of GlaxoSmithKlines Business Segments
12:10PM  GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake at Insider Monkey
11:46AM  GlaxoSmithKlines Revenue Trend for 4Q16
11:17AM  Gilead Sciences: Not Out of the Woods Yet? at
09:32AM  Lilly's Olumiant Gets Marketing Authorization in Europe
03:47AM  Gilead challenges GSK with strong HIV drug data
Feb-13-17 08:40PM  Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference
07:55PM  PRESS DIGEST- Financial Times - Feb 14
06:45PM  [$$] GSK claims new HIV combination therapy will be 'less harmful' at Financial Times
04:25PM  Can Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry?
10:41AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017
Feb-10-17 11:09AM  Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
09:06AM  GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017
06:44AM  Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
Feb-09-17 12:58PM  Gilead to Battle GlaxoSmithKline for HIV Cure at Investopedia
10:36AM  Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View
Feb-08-17 08:30PM  PRESS DIGEST- British Business - Feb 9
04:21PM  Allergan Leads Drug Stocks On View-Crushing Q4, 2016, 2017 Guidance
01:30PM  [$$] GSK beats forecasts but braces for asthma drug challenge at Financial Times
01:28PM  Gilead: Where's the Bottom? at
12:22PM  FTSE 100 ekes out a slight gain ahead of key Brexit vote at MarketWatch
12:22PM  Vaccine Sales Help GSK Results, Shares Up at Investopedia
11:57AM  GSK warns profits to be hit by generic drugs competition
11:54AM  [$$] GlaxoSmithKline Warns of Hit From Advair Copycat at The Wall Street Journal
11:50AM  GlaxoSmithKline and Gilead to face off at HIV meeting next week
09:51AM  Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y
09:47AM  GSK CEO on Drug Pricing, Regulation, Succession
08:48AM  Glaxo posts 4Q profit
08:17AM  GSK CEO: US health-care system could benefit from more tr...
08:16AM  GSK beats Street on top and bottom line
07:31AM  Glaxo Beats Expectations For Q4 Earnings; Shares Fall On Advair Concerns
07:17AM  Weak pound buoys GSK but drugmaker warns on 2017 generic threat
01:28AM  CEO Witty will leave GSK on a high: Novasecta
Feb-07-17 09:45AM  Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc. at Motley Fool
09:06AM  Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More
08:53AM  Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus
07:16AM  Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline at Motley Fool
Feb-06-17 07:51AM  New GlaxoSmithKline CEO prepares for R&D choices, potential deals
06:22AM  Brexit Already Having a Negative Impact, Business Leaders Say
Feb-03-17 04:30PM  GSK North American president: Health care spending in N.C. will crowd out education, transportation needs at
09:06AM  Why the Majority of Analysts Deem Novartis a Buy
Feb-02-17 11:03AM  Advair, Armonair From Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets FDA Approval at Insider Monkey
10:53AM  Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks at Motley Fool
06:42AM  GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
Feb-01-17 03:05PM  Weighing the Foreign Exchange Impact on Novartiss Revenues in 4Q16
Jan-31-17 11:29AM  Healthcare Names Rally as Pharma Meets with Trump at Investopedia
09:48AM  Trump says drug prices are 'astronomical' at MarketWatch
08:28AM  How a 300-Year Old Drug Company Is Changing the World at Motley Fool
Jan-30-17 11:24AM  As Teva wins US approval for GSK Advair copy, main fight yet to come Reuters
07:37AM  TAF-Based HIV Strategy May Boost Gilead Sciencess Long-Term Growth
12:00AM  [$$] Looking for a new chief? Let the office 'Hunger Games' begin at Financial Times
Jan-29-17 11:26PM  Whats the Secret Ingredient in That Pizza Crust? Antacid at The Wall Street Journal
Jan-28-17 04:58PM  Can Novavax Stay Ahead of the Competition? at Motley Fool
Jan-27-17 06:04AM  Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint
Jan-26-17 05:50PM  With new Bay Area presence, Singapore fund invests $800M in Alphabet-created Verily at
03:28PM  Is GlaxoSmithKline's Dividend Sustainable? at Motley Fool
01:30PM  Alphabet's life science spinoff raises $800M from Singapore investor at
09:28AM  11 Largest Pharmaceutical Companies In The World at Insider Monkey
06:02AM  GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000
Jan-25-17 12:08PM  Q4 Earnings Scorecard and Analyst Reports for Tesla, Verizon & Others
Jan-24-17 07:36AM  What Do Analysts Recommend for Johnson & Johnson?
Jan-23-17 07:38AM  Analysts Expect Negative Growth for Novartis in 4Q16
Jan-22-17 03:24PM  Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson at Motley Fool
Jan-21-17 02:02PM  5 Drugs That Are Way Cheaper in Canada at Motley Fool
Jan-20-17 05:41PM  Novartiss 4Q16 Earnings: What Is Expected?
10:00AM  Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
Jan-19-17 01:15PM  Why is Pharma Struggling to Grow EPS? at Investopedia
06:55AM  Glaxo CEO Seeks Greater Transparency on Drug Pricing
05:13AM  GSK grabs Astra executive to replace pharma head
02:15AM  GSK grabs Astra executive to replace exiting pharma head
Jan-18-17 05:00PM  Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics at Bloomberg
Jan-17-17 01:38PM  In This Case Silence Could be Golden at Investopedia
Jan-16-17 10:37AM  How Is Novartiss Revenue Trending?
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company operates through five segments: Global Pharmaceuticals, HIV, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas under the Sensodyne, Horlicks, Parodontax, Poligrip, Voltaren, Panadol, Otrivin, Tums, Flonase, Eno, and Theraflu brand names. GlaxoSmithKline plc offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and creams. The company has a strategic collaboration with Miltenyi Biotec GmbH to develop a cell and gene therapy automation and processing technology; and a partnership with Fimbrion Therapeutics for the development of a small molecule drug to treat prevent urinary tract infections. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GLAXOSMITHKLINE PLC10% OwnerOct 24Buy14.0066,500931,0003,220,627Oct 26 05:49 PM